The Use of Secukinumab in Psoriatic Patients: A Single Center Study in Morocco

Abstract

Introduction: Psoriasis is an immune cell-mediated inflammatory skin disease, characterized by the formation of scaly, indurated, erythematous plaques. Psoriasis comorbidities and symptoms affect the choice of treatments. Secukinumab is a fully human monoclonal anti-body that selectively neutralizes IL-17A and has proven to be effective in the treatment of multiple manifestations of psoriatic disease. Materials and Methods: In this prospective descriptive study of 13 patients with moderate to severe psoriasis in the Department of Dermatology at Ibn Sina University Hospital in Rabat between 2022 and 2024, we focus on the treatment of psoriasis with Secukinumab. All our patients received more than 6 injections of Secukinumab. Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, and percentage of patients achieving PASI 75/90/100, at weeks 4 and 16. Results: In this study, 13 patients with severe psoriasis with a PASI>10 were included. The mean age at diagnosis was 44.7 years and the mean duration of the disease before diagnosis was 5 years. All our patients received Secukinumab following this protocol (subcutaneous injection of 300mg at weeks 0,1,2,3 and 4, followed by 300mg every 4 weeks) and the PASI 75, PASI 90, PASI 100 was evaluated respectively. At week 4, 69.2% of patients still on Secukinumab had experienced at least a 50% reduction in PASI (PASI 50) from baseline. At week 16, the proportions of patients achieving PASI 75, PASI 90, and PASI 100 were: 23,1%, 30,7%, (46,2%) respectively. Adverse events possibly relevant to Secukinumab therapy were not reported in our patients Conclusion: To improve the quality of life of psoriatic patients, the choice of available treatments is now increasing. Secukinumab showed sustained effectiveness and favorable safety profile in patients with moderate to severe psoriasis in our patients.